Your browser doesn't support javascript.
loading
Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120.
deCamp, Allan C; Rolland, Morgane; Edlefsen, Paul T; Sanders-Buell, Eric; Hall, Breana; Magaret, Craig A; Fiore-Gartland, Andrew J; Juraska, Michal; Carpp, Lindsay N; Karuna, Shelly T; Bose, Meera; LePore, Steven; Miller, Shana; O'Sullivan, Annemarie; Poltavee, Kultida; Bai, Hongjun; Dommaraju, Kalpana; Zhao, Hong; Wong, Kim; Chen, Lennie; Ahmed, Hasan; Goodman, Derrick; Tay, Matthew Z; Gottardo, Raphael; Koup, Richard A; Bailer, Robert; Mascola, John R; Graham, Barney S; Roederer, Mario; O'Connell, Robert J; Michael, Nelson L; Robb, Merlin L; Adams, Elizabeth; D'Souza, Patricia; Kublin, James; Corey, Lawrence; Geraghty, Daniel E; Frahm, Nicole; Tomaras, Georgia D; McElrath, M Juliana; Frenkel, Lisa; Styrchak, Sheila; Tovanabutra, Sodsai; Sobieszczyk, Magdalena E; Hammer, Scott M; Kim, Jerome H; Mullins, James I; Gilbert, Peter B.
Afiliación
  • deCamp AC; Vaccine and Infectious Disease Division and Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Rolland M; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
  • Edlefsen PT; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, United States of America.
  • Sanders-Buell E; Vaccine and Infectious Disease Division and Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Hall B; Department of Biostatistics, University of Washington, Seattle, Washington, United States of America.
  • Magaret CA; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
  • Fiore-Gartland AJ; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, United States of America.
  • Juraska M; Department of Microbiology, University of Washington, Seattle, Washington, United States of America.
  • Carpp LN; Vaccine and Infectious Disease Division and Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Karuna ST; Vaccine and Infectious Disease Division and Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Bose M; Vaccine and Infectious Disease Division and Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • LePore S; Vaccine and Infectious Disease Division and Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Miller S; Vaccine and Infectious Disease Division and Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • O'Sullivan A; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
  • Poltavee K; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, United States of America.
  • Bai H; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
  • Dommaraju K; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, United States of America.
  • Zhao H; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
  • Wong K; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, United States of America.
  • Chen L; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
  • Ahmed H; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, United States of America.
  • Goodman D; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
  • Tay MZ; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, United States of America.
  • Gottardo R; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
  • Koup RA; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, United States of America.
  • Bailer R; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
  • Mascola JR; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, United States of America.
  • Graham BS; Department of Microbiology, University of Washington, Seattle, Washington, United States of America.
  • Roederer M; Department of Microbiology, University of Washington, Seattle, Washington, United States of America.
  • O'Connell RJ; Department of Microbiology, University of Washington, Seattle, Washington, United States of America.
  • Michael NL; Department of Biology, Emory University, Atlanta, Georgia, United States of America.
  • Robb ML; Duke Human Vaccine Institute, Duke University, Durham, North Carolina, United States of America.
  • Adams E; Duke Human Vaccine Institute, Duke University, Durham, North Carolina, United States of America.
  • D'Souza P; Vaccine and Infectious Disease Division and Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
  • Kublin J; Department of Biostatistics, University of Washington, Seattle, Washington, United States of America.
  • Corey L; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Geraghty DE; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Frahm N; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Tomaras GD; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
  • McElrath MJ; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Frenkel L; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
  • Styrchak S; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, United States of America.
  • Tovanabutra S; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
  • Sobieszczyk ME; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, United States of America.
  • Hammer SM; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
  • Kim JH; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, United States of America.
  • Mullins JI; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, United States of America.
  • Gilbert PB; Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
PLoS One ; 12(11): e0185959, 2017.
Article en En | MEDLINE | ID: mdl-29149197
Although the HVTN 505 DNA/recombinant adenovirus type 5 vector HIV-1 vaccine trial showed no overall efficacy, analysis of breakthrough HIV-1 sequences in participants can help determine whether vaccine-induced immune responses impacted viruses that caused infection. We analyzed 480 HIV-1 genomes sampled from 27 vaccine and 20 placebo recipients and found that intra-host HIV-1 diversity was significantly lower in vaccine recipients (P ≤ 0.04, Q-values ≤ 0.09) in Gag, Pol, Vif and envelope glycoprotein gp120 (Env-gp120). Furthermore, Env-gp120 sequences from vaccine recipients were significantly more distant from the subtype B vaccine insert than sequences from placebo recipients (P = 0.01, Q-value = 0.12). These vaccine effects were associated with signatures mapping to CD4 binding site and CD4-induced monoclonal antibody footprints. These results suggest either (i) no vaccine efficacy to block acquisition of any viral genotype but vaccine-accelerated Env evolution post-acquisition; or (ii) vaccine efficacy against HIV-1s with Env sequences closest to the vaccine insert combined with increased acquisition due to other factors, potentially including the vaccine vector.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antígenos CD4 / Proteína gp120 de Envoltorio del VIH / VIH-1 / Vacunas contra el SIDA Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antígenos CD4 / Proteína gp120 de Envoltorio del VIH / VIH-1 / Vacunas contra el SIDA Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos